A study on comparison of the effect of intravenous Tranexamic acid and sublingual Misoprostol in reducing blood loss during caeserean section

Comparative study on the effect of intravenous Tranexamic acid and sublingual Misoprostol in reducing blood loss during caeserean section - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067355

Enrollment

156

Registered

2024-05-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O60-O77- Complications of labor and delivery

Interventions

Intervention1: INTRAVENOUS TRANEXAMIC ACID: Group A- Patients will receive 1gram of Tranexamic acid injected intravenously in 100ml of Normal saline 10 minutes before starting Caeserean section. Both

Eligibility

Inclusion criteria

Inclusion criteria: 1.Term pregnancy more than or equal to 37 weeks of gestation. 2.Singleton pregnancy undergoing emergency / elective caeserean section.

Exclusion criteria

Exclusion criteria: 1.Antepartum hemorrhage( abruptio placenta, placenta previa) 2.Any underlying disease ( Heart, Liver, Pulmonary) 3.Allergic to Tranexamic acid and Misoprostol 4.Coagulation disorders. 5.Intrauterine fetal demise 6.Fibroid 7.DIC, Anticoagulant therapy 8.Previous history of uterine rupture 9.Multiple pregnancy. 10.Polyhydramnios 11.Category 1 caeserean section ( example: cord prolapse) 12.Caeserean section under general anesthesia

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of Intravenous Tranexamic acid and sublingual Misoprostol in reducing blood loss during Caeserean sectionTimepoint: 1.Blood loss during Caeserean section,which is assessed by Soaked mop count and by suction volume excluding the amniotic fluid 2. Post opertaive hemoglobin and hematocrit after 48 hours. 3.Total amount of blood loss 48 hours post surgery	—

Secondary

Measure	Time frame
1.To compare the safety profile of both drugs. 2.To assess if there is need for any additional uterotonic usage / blood transfusion.Timepoint: Post operative hemoglobin d hematocrit after 48 hours.	—

Countries

India

Contacts

Public ContactSHAGINA BANU G

SRI MANAKULA VINAYAGAR MEDICAL COLLEGE AND HOSPITAL

niveog91@yahoo.com9994328253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026